Anistreplase: An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents.Thrombolytic Therapy: Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts.Streptokinase: Streptococcal fibrinolysin . An enzyme produced by hemolytic streptococci. It hydrolyzes amide linkages and serves as an activator of plasminogen. It is used in thrombolytic therapy and is used also in mixtures with streptodornase (STREPTODORNASE AND STREPTOKINASE). EC 3.4.-.Controlled Clinical Trials as Topic: Works about clinical trials involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicines, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trials are characterized as RANDOMIZED CONTROLLED TRIALS AS TOPIC.Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).Fibrinolytic Agents: Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.Encyclopedias as Topic: Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)Penicillins: A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065)Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.Penicillin Amidase: An enzyme catalyzing the hydrolysis of penicillin to penicin and a carboxylic acid anion. EC 3.5.1.11.Carbenicillin: Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.Journal Impact Factor: A quantitative measure of the frequency on average with which articles in a journal have been cited in a given period of time.Pharmacology: The study of the origin, nature, properties, and actions of drugs and their effects on living organisms.Pharmacology, Clinical: The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans.Publishing: "The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.Bibliometrics: The use of statistical methods in the analysis of a body of literature to reveal the historical development of subject fields and patterns of authorship, publication, and use. Formerly called statistical bibliography. (from The ALA Glossary of Library and Information Science, 1983)Journalism, Medical: The collection, writing, and editing of current interest material on topics related to biomedicine for presentation through the mass media, including newspapers, magazines, radio, or television, usually for a public audience such as health care consumers.Pentosan Sulfuric Polyester: A sulfated pentosyl polysaccharide with heparin-like properties.Cystitis, Interstitial: A condition with recurring discomfort or pain in the URINARY BLADDER and the surrounding pelvic region without an identifiable disease. Severity of pain in interstitial cystitis varies greatly and often is accompanied by increased urination frequency and urgency.Protective Devices: Devices designed to provide personal protection against injury to individuals exposed to hazards in industry, sports, aviation, or daily activities.Heparin: A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.Heparitin Sulfate: A heteropolysaccharide that is similar in structure to HEPARIN. It accumulates in individuals with MUCOPOLYSACCHARIDOSIS.Physician-Patient Relations: The interactions between physician and patient.Ambulances: A vehicle equipped for transporting patients in need of emergency care.Tissue Plasminogen Activator: A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.Emergency Medical Services: Services specifically designed, staffed, and equipped for the emergency care of patients.Antithrombin Proteins: An endogenous family of proteins belonging to the serpin superfamily that neutralizes the action of thrombin. Six naturally occurring antithrombins have been identified and are designated by Roman numerals I to VI. Of these, Antithrombin I (see FIBRIN) and ANTITHROMBIN III appear to be of major importance.Antithrombins: Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.Anticoagulants: Agents that prevent clotting.beta-Alanine: An amino acid formed in vivo by the degradation of dihydrouracil and carnosine. Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID. A rare genetic disorder, hyper-beta-alaninemia, has been reported.Pipecolic AcidsBenzimidazoles: Compounds with a BENZENE fused to IMIDAZOLES.Hirudins: Single-chain polypeptides of about 65 amino acids (7 kDa) from LEECHES that have a neutral hydrophobic N terminus, an acidic hydrophilic C terminus, and a compact, hydrophobic core region. Recombinant hirudins lack tyr-63 sulfation and are referred to as 'desulfato-hirudins'. They form a stable non-covalent complex with ALPHA-THROMBIN, thereby abolishing its ability to cleave FIBRINOGEN.Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)Plasminogen: Precursor of plasmin (FIBRINOLYSIN). It is a single-chain beta-globulin of molecular weight 80-90,000 found mostly in association with fibrinogen in plasma; plasminogen activators change it to fibrinolysin. It is used in wound debriding and has been investigated as a thrombolytic agent.Equipment Design: Methods of creating machines and devices.Magnetite Nanoparticles: Synthesized magnetic particles under 100 nanometers possessing many biomedical applications including DRUG DELIVERY SYSTEMS and CONTRAST AGENTS. The particles are usually coated with a variety of polymeric compounds.Nanoparticles: Nanometer-sized particles that are nanoscale in three dimensions. They include nanocrystaline materials; NANOCAPSULES; METAL NANOPARTICLES; DENDRIMERS, and QUANTUM DOTS. The uses of nanoparticles include DRUG DELIVERY SYSTEMS and cancer targeting and imaging.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Magnetic Resonance Spectroscopy: Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING).Magnetics: The study of MAGNETIC PHENOMENA.Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.Heart: The hollow, muscular organ that maintains the circulation of the blood.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.Heart Rate: The number of times the HEART VENTRICLES contract per unit of time, usually per minute.

Thrombolytic therapy in Europe: current status. (1/39)

Thrombolytic therapy is a practical, effective approach to the management of acute myocardial infarction that is widely used in Europe today. Early European trials demonstrated a clear reduction in mortality in patients who received thrombolytic therapy compared with those given conventional treatment. The findings of experimental studies suggest that early reperfusion of the infarct-related artery reduces myocardial damage, which results in the preservation of left ventricular function and, in turn, may improve survival. Although tissue plasminogen activator (t-PA) has been shown to produce more rapid and complete reperfusion than streptokinase, two large-scale clinical trials in which t-PA was given as a standard 3- or 4-h infusion provided no evidence of a survival advantage with this agent. However, the accelerated t-PA regimen used in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) study was associated with a lower mortality than streptokinase or a combination of t-PA and streptokinase, thus lending support to the 'open artery' theory. Two recent studies conducted in Europe, the Grampian Region Early Anistreplase Trial (GREAT) and the European Myocardial Infarction Project (EMIP), have demonstrated the feasibility, safety, and efficacy of early thrombolytic therapy before admission to hospital. In GREAT, anistreplase (APSAC) was administered at home by general practitioners. In EMIP, this same agent was given by emergency medical personnel. In both studies, pre-hospital administration reduced the time between the onset of symptoms and initiation of thrombolysis and was associated with a lower mortality rate. Recent data from the European Cooperative Group Study show that the benefits of thrombolytic therapy are maintained for up to 5 years. Research continues in an effort to develop safer and more effective thrombolytic agents. Educational efforts to familiarize the public with the symptoms of myocardial infarction and the development of more rapid, efficient emergency response systems may also improve the outcome of thrombolytic therapy by shortening the time between symptom onset and thrombolytic drug administration.  (+info)

Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG. (2/39)

OBJECTIVE: To examine the induction of antistreptokinase antibodies after giving streptokinase or anistreplase to patients with acute myocardial infarction. DESIGN: Patients were randomly allocated to receive either 1.5 x 10(6) IU, streptokinase or 30U anistreplase in a double blind study. Blood samples were collected immediately before treatment and subsequently at intervals up to 30 months; plasma samples were assayed for streptokinase resistance titre (functional assay) and streptokinase binding by IgG (microradioimmunoassay). SETTING: Cardiology department in a general hospital. PATIENTS: 128 consecutive eligible patients. Samples were collected for up to one year according to a prospective design: a subsection of 47 patients was selected for intensive study over the first 14 days. After one year, all available patients (67) were sampled on one further occasion. RESULTS: Antibody responses to streptokinase and anistreplase were similar. Streptokinase resistance titres exceeded pretreatment concentrations five days after dosing, and values peaked at 14 days. By 12 months after dosing, 92% of resistance titres (n = 84) had returned to within the pretreatment range. Antistreptokinase IgG concentrations also exceeded baseline concentrations within five days and peaked at 14 days. Half of the individual values had returned to within the pretreatment range by 12 months (n = 84) and 89% by 30 months (n = 18). CONCLUSION: Although we cannot be sure of the clinical significance, because of the increased likelihood of resistance due to antistreptokinase antibody, streptokinase and anistreplase may not be effective if administered more than five days after an earlier dose of streptokinase or anistreplase, particularly between five days and 12 months, and increased antistreptokinase antibody may increase the risk of allergic-type reactions.  (+info)

Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group. (3/39)

OBJECTIVE: To assess the feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners. DESIGN: Randomised double blind parallel group trial of anistreplase 30 units intravenously and placebo given either at home or in hospital. SETTING: 29 rural practices in Grampian admitting patients to teaching hospitals in Aberdeen (average distance 36 (range 16-62) miles). PATIENTS: 311 patients with suspected acute myocardial infarction and no contraindications to thrombolytic therapy seen at home within four hours of onset of symptoms. MAIN OUTCOME MEASURES: Time saving, adverse events, Q wave infarction, left ventricular function. RESULTS: Anistreplase was administered at home 101 minutes after onset of symptoms, while anistreplase was given in hospital 240 minutes after onset of symptoms (median times). Adverse events after thrombolysis were infrequent and, apart from cardiac arrest, not a serious problem when they occurred in the community: seven of 13 patients were resuscitated after cardiac arrest out of hospital. By three months after trial entry the relative reduction of deaths from all causes in patients given thrombolytic therapy at home was 49% (13/163 (8.0%) v 23/148 (15.5%); difference -7.6% (95% confidence interval -14.7% to -0.4%), p = 0.04). Full thickness Q wave infarction was less common in patients with confirmed infarction receiving treatment at home (65/122 (53.3%) v 76/112 (67.9%); difference -14.6% (95% confidence interval -27.0% to -2.2%), p = 0.02). CONCLUSIONS: General practitioners provided rapid pre-hospital coronary care of a high standard. Compared with later administration in hospital, giving anistreplase at home resulted in reduction in mortality, fewer cardiac arrests, fewer Q wave infarcts, and better left ventricular function. Benefits were most marked where thrombolytic therapy was administered within two hours of the onset of symptoms.  (+info)

Oesophageal dissection after thrombolytic treatment for myocardial infarction. (4/39)

A 62 year old woman admitted with a history suggesting acute myocardial infarction had thrombolytic treatment with anisoylated plasminogen-streptokinase activator complex, which resulted in submucosal haemorrhage in the oesophagus; this caused dissection of the wall of the oesophagus and complete dysphagia. The haematoma resolved spontaneously, leaving behind a diverticulum, with reduced peristalsis and delayed emptying but no obstruction.  (+info)

The pharmacological modulation of thrombin-induced cerebral thromboembolism in the rabbit. (5/39)

1. Intracarotid (i.c.) administration of thrombin induced a marked accumulation of 111indium-labelled platelets and 125I-labelled fibrinogen within the cranial vasculature of anaesthetized rabbits. 2. Thrombin (100 iu kg-1, i.c.) - induced platelet accumulation was completely abolished by pretreatment with desulphatohirudin (CGP 39393; 1 mg kg-1 i.c., 1 min prior to thrombin). Administration of CGP 39393 1 or 20 min after thrombin produced a significant reduction in platelet accumulation. 3. Intravenous (i.v.) administration of the platelet activating factor (PAF) receptor antagonist BN 52021 (10 mg kg-1) 5 min prior to thrombin (100 iu kg-1, i.c.) had no effect on platelet accumulation. 4. An inhibitor of NO biosynthesis, L-NG-nitro arginine methyl ester (L-NAME; 100 mg kg-1, i.c.), had no significant effect on the cranial platelet accumulation response to thrombin (10 iu kg-1, i.c.) when administered 5 min prior to thrombin. 5. Defibrotide (32 or 64 mg kg-1 bolus i.c. followed by 32 or 64 mg kg-1 h-1, i.c., infusion for 45 min) treatment begun 20 min after thrombin (100 iu kg-1, i.c.) did not significantly modify the cranial platelet accumulation response. 6. Cranial platelet accumulation induced by thrombin (100 iu kg-1, i.c.) was significantly reversed by the fibrinolytic drugs urokinase (20 iu kg-1, i.c., infusion for 45 min), anisoylated plasminogen streptokinase activator complex (APSAC) (200 micrograms kg-1, i.v. bolus) or recombinant tissue plasminogen activator (rt-PA; 100 micrograms kg-1, i.c. bolus followed by 20 micrograms kg-1 min-1, i.c., infusion for 45 min) administered 20 min after thrombin.8. These results suggest that neither endogenous PAF nor NO modulate thrombin-induced intracranial platelet accumulation in the rabbit. However, fibrin deposition appears to play an important role as shown by the ability of fibrinolytic agents to reverse platelet and fibrinogen accumulation induced by i.c. thrombin.  (+info)

Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis. (6/39)

PURPOSE: Over the past 2 decades the use of thrombolytic therapy in the management of peripheral occlusive diseases, most notably peripheral arterial occlusion (PAO) and deep venous thrombosis (DVT), has become an accepted and potentially preferable alternative to surgery. We examined the period when urokinase was in short supply and subsequently unavailable, to explore potential differences in clinical outcome and economic effect between urokinase and recombinant tissue plasminogen activator (rt-PA). MATERIAL AND METHODS: Data were obtained from the Premier Perspective Database, a broad clinical database that contains information on inpatient medical practices and resource use. The study population included all patients hospitalized in 1999 and 2000 with a primary or secondary diagnosis of PAO or DVT. Incidence was calculated for common adverse events, including bleeding complications, intracranial hemorrhage, amputation, and death. Cost data were also abstracted from the database, and are expressed as mean +/- SD. RESULTS: Demographic variables were similar in the urokinase and rt-PA groups. The rate of bleeding complications was similar in the urokinase and rt-PA groups. There were no intracranial hemorrhages in the urokinase group, compared with a rate of 1.5% in the rt-PA PAO group (P = .087) and 1.9% in the rt-PA DVT group (P = .175). The in-hospital mortality rate was lower in the urokinase-treated PAO subgroup (3.6% vs 8.5%; P = .026), but a similar finding in the DVT subgroup did not achieve statistical significance (4% vs 9.8%; P = .069). While pharmacy costs were greater in the urokinase-treated group (US 5472 dollars +/- US 5579 dollars vs US 3644 dollars +/- US 6009 dollars, P < .001; PAO subgroup, US 11,070 dollars +/- US 15,409 dollars vs US 6150 dollars +/- US 12,398 dollars, P = .003), overall hospital costs did not differ significantly between the 2 groups. This finding appears to be explained by a shorter hospital stay and reduced room and board costs in the urokinase-treated group. CONCLUSION: There were significant differences in outcome in patients with PAO and DVT who received treatment with urokinase and rt-PA. While pharmacy costs were significantly greater when urokinase was used, reduction in length of stay accounted for similar total hospital costs compared with rt-PA. These findings must be considered in the context of the retrospective nature of the analysis and the potential to use dosing regimens that differ from those in this study.  (+info)

Serum myoglobin and creatine kinase enzymes in acute myocardial infarction treated with Anistreplase. (7/39)

AIMS: To compare plasma myoglobin concentration and cardiac enzyme activity with electrocardiographic (ECG) changes in two groups of patients (reperfused and non-reperfused) participating in a placebo-controlled randomised double blind trial of treatment of myocardial infarction (MI) with intravenous thrombolytic therapy (Anistreplase). METHODS: Twenty two patients with confirmed MI obeying strict inclusion and exclusion criteria were studied. Plasma myoglobin was measured by radioimmunoassay and creatine kinase enzyme (CK and CKMB) by NAC activated and NAC activated/immunoinhibition methods respectively in all patients before and at frequent intervals after injection of Anistreplase or placebo. Patients were divided into reperfused (R) and non-reperfused (NR) groups on the basis of ECG criteria. Reperfusion was diagnosed if the measured ST segment elevation fell by greater than or equal to 50% at 2 hours post dosing. RESULTS: The time to peak (TTP) myoglobin was significantly less in the R group compared with the NR group but there was considerable overlap in the range of values. The area under the enzyme time curves (AUCs) and summed ST segment epsilon ST elevations were significantly smaller in the R compared with the NR group. CONCLUSIONS: Although TTP myoglobin results were significantly lower in the R group, TTP myoglobin will probably not be useful as an non-invasive indicator of reperfusion because of the overlap in values between the two groups. The significant reduction in the AUC and epsilon ST only in the R group suggests decreased infarct size. However, in this small preliminary study reperfusion did not occur more frequently with Anistreplase than without.  (+info)

Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. (8/39)

The thrombolytic and systemic effects of BM 06.022 were evaluated and compared with those of alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. BM 06.022 consists of the kringle-2 and protease domains of human tissue plasminogen activator (t-PA) and is unglycosylated because of its expression in Escherichia coli cells. Thrombus formation in anesthetized open chest dogs was induced by electrical injury to the intimal surface of the left circumflex coronary artery at a high level site of obstruction. In heparinized dogs, none of six vehicle-treated animals exhibited reperfusion. Reperfusion was achieved in four of six dogs at 18.3 +/- 6 min after intravenous bolus injection of 140 kU/kg (0.24 mg/kg) of BM 06.022, whereas four of six dogs exhibited reperfusion later (p less than 0.05) at 76.5 +/- 16.1 min during infusion of 1.33 mg/kg of alteplase (0.13 mg/kg as initial bolus injection, followed by 0.66 mg/kg over 1 h and 0.53 mg/kg over 2 h). Significantly later (p less than 0.05) reperfusion than that achieved with BM 06.022 was achieved in five of six dogs at 57.8 +/- 12.1 min after intravenous injection of 0.4 U/kg of anistreplase. Streptokinase (21,000 IU/kg over 60 min) and urokinase (20,000 IU/kg as an intravenous bolus injection, followed by 20,000 IU/kg over 89 min) each induced reperfusion in three of six dogs but at 67 +/- 12 and 84.3 +/- 17.1 min (p less than 0.05 vs. BM 06.022), respectively.(ABSTRACT TRUNCATED AT 250 WORDS)  (+info)

ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction Academic Article ...
One measure of the success of thrombolysis is the early patency status of the infarct-related coronary artery. The Thrombolysis in Myocardial Infarction (TIMI) study group designated patency grades 0 (occluded) or 1 (minimal perfusion) as thrombolysis failure and grade 2 (partial perfusion) or 3 (complete perfusion) as success. To evaluate their true functional significance, perfusion grades were compared with enzymatic and electrocardiographic (ECG) indexes of myocardial infarction in 359 patients treated within 4 h with anistreplase (APSAC) or streptokinase. Serum enzymes and ECGs were assessed serially. Patency was determined at 90 to 240 min (median 2.1 h) and graded by an observer who had no knowledge of patient data.. Results for the two drug arms were similar and combined. Distribution of patency was grade 0 = 20%, n = 72; grade 1 = 8%, n = 27; grade 2 = 16%, n = 58 and grade 3 = 56%, n = 202. Interventions were performed after angiography but within 24 h in 51% (n = 37), 70% (n = 19), ...
The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction. The DDD of urokinase is based on treatment of acute lung emboli. The DDDs are either expressed in international units or gram ...
An initiative of Alzheimers Australia, this website is a practical and comprehensive resource to help people to plan ahead for their future. It gives the information needed to make decisions and helps to put decisions into action. Resources include worksheets to help people step through the processes involved in planning ahead. It also has information and up to date links for all States and Territories as well as information available in 30 languages.. ...
All trials randomized patients to fibrinoltyic therapy or control. Treatment for each trial was as follows: GISSI-1: streptokinase (SK), 1.5 MU vs open control ISAM: SK, 1.5 MU vs placebo; single IV bolus aspirin; IV heparin, 5000 U + 800-1000 U/h for 72-96 h AIMS: APSAC, 30 U vs placebo; IV heparin at 6 h, 1000-1500 U/h ISIS-2: SK, 1.5 MU vs placebo; aspirin ASSET: tPA, 100 mg vs placebo; IV heparin, 5000 U + 1000 U/h for 24 h USIM: urokinase, 1 MU x 2 bolus vs open control; IV heparin, 10000 U + 1000 U/h for 48 h ISIS-3: SK, 1.5 MU or tPA, 0.6 MU/kg or APSAC, 30 U vs open control; aspirin; SC heparin, 12500 U bd for 7 days EMERAS: SK, 1.5 MU vs placebo; aspirin LATE: tPA, 100 mg vs placebo; aspirin; IV heparin, 5000 U + 1000 U/h for 48 h. ...
Westhill Academy, Grampian Region: A Report by HM Inspectors of Schools by Great Britain, 9780748048748, available at Book Depository with free delivery worldwide.
There is a need for a simple clinical measurement that will indicate the extent of myocardial salvage after successful thrombolysis. This study examined whether coronary artery reperfusion reduced the infarct size as assessed electrocardiographically after thrombolytic treatment. The sum of the (sigma) ST segment area in leads showing ST segment elevation in the 12 lead electrocardiogram at presentation was used as an index of potential myocardial injury (initial ischaemic index). The evolved infarct size at 48 h was assessed by a QRS scoring system. Two groups of patients, both admitted with anterior myocardial infarction within 6 h of onset, were studied. Group 1 (n = 35) received analgesia only and group 2 (n = 33) received thrombolytic treatment either by the intracoronary (streptokinase, n = 13) or intravenous route (anistreplase, n = 20). Reperfusion was assessed angiographically. The mean (SD) potential infarct size assessed by the initial ischaemic index was similar in both groups (group ...
Grampians Tourism: TripAdvisor has 27,600 reviews of Grampians Hotels, Attractions, and Restaurants making it your best Grampians resource.
This half day workshop will deliver an interactive workshop for PCAs working in community and aged care. The workshop is designed to enhance your skills and develop a better understanding about Symptom Management and a Palliative Approach for older people living in residential aged care or the community.. ...
Victoria, West Victoria, Grampians. Located 260 kms west of Melbourne, the Grampians have a lot to offer the traveller. Spectacular rock formations, mountains and scenery make it a popular getaway. For the 4wder, there are numerous 4wd tracks to explore.
Eventbrite - ACK presents PAMIS Family Fun Day - Grampian - Saturday, 15 July 2017 at Aberdeen Sports Village - Sports Centre, Aberdeen, Scotland. Find event and ticket information.
In 2005 Chest Heart & Stroke Scotland (CHSS), in partnership with NHS Grampian, identified the need for specialist training for nurses and other health professionals working with stroke patients and their families.. With the appointment of a stroke education facilitator, NHS Grampian has been successfully providing education, training courses and study days throughout the region.. The courses have been designed as:. ...
Professor Lovell held high positions in the American Society for Testing and Materials (ASTM), the American Society of Civil Engineers (ASCE), the Transportation Research Board, and other professional organizations, from which he received numerous awards. He was a Fellow of both the ASTM and the ASCE. He was a past district governor of Lions International, a past president of the Lafayette Lions Club, a member of the Board of Directors of the Lafayette Rotary Club, a past president of the Greater Lafayette Civic Theatre, a charter member of the Covenant Presbyterian Church, West Lafayette, and an elder of the Central Presbyterian Church, Lafayette ...
Ballarat & Grampians Private Practice (B&GPP) is a business unit of Ballarat Health Services. The B&GPP provides space for medical specialists to operate their own private practice within Ballarat Health Services.
Tinelli, Michela, Scotland, Graham and Watson, Margaret (2009) An economic evaluation of the NHS Grampian Opportunistic Chlamydia Screening Study. . University of Aberdeen, Aberdeen, UK. ...
Every effort has been made to acknowledge the original authors of any external images used. But on the most part images and content in this blog are copyrighted to Margaret Lawson (c) 2013. All rights reserved ...
Common areas. As is expected of such a long-established, community based facility you will feel as though you are entering a calm and welcoming home-like environment. Residents are provided with large, open lounge areas, comfortably furnished with individual recliner chairs and couches, and large TV (LCD) screens for ease of viewing, or may escape into quieter sitting rooms. Fresh, daily-made meals are served in the large open dining areas or alternatively there is access to a private dining room for residents and family, designed to make you feel relaxed and at home.. Sweeping gardens with uninterrupted views to the Grampians provide space to stroll and relax within private and secure outdoor areas that incorporate courtyards, established trees, manicured gardens and raised garden beds, and peaceful retreats maintained by community volunteers. All of this and yet only a short walk into the centre of town, where an array of shops and local businesses boast services for your convenience.. In ...
Thrombolytic drugs are widely used for the management of cerebral venous sinus thrombosis patients. Several in vitro models have been developed to study clot lytic activity of thrombolytic drugs, but all of these have certain limitations. There is need of an appropriate model to check the clot lytic efficacy of thrombolytic drugs. In the present study, an attempt has been made to design and develop a new model system to study clot lysis in a simplified and easy way using a thrombolytic drug, streptokinase. Whole blood from healthy individuals (n = 20) was allowed to form clots in a pre-weighed sterile microcentrifuge tubes; serum was removed and clot was weighed. After lysis by streptokinase fluid was removed and remnants of clot were again weighed along with the tube. Percentage of Clot lysis was calculated on the basis of the weight difference of microcentrifuge tubes obtained before and after clot lysis. There was a significant percentage of clot lysis observed when streptokinase was used. On the
In GREAT, median call-to-needle times were 55 and 185 minutes for prehospital and hospital groups; 90% and 1% of measurements were ⩽ 90 minutes, respectively.1 In this audit, comprising many of the same practices that took part in the trial, the corresponding times were improved, at 45 minutes for prehospital thrombolysis, and 145 minutes for hospital thrombolysis. The improvement is most marked for the hospital group, where call-to-needle times were 40 minutes shorter in the audit than in the trial. This was largely owing to shortening of door-to-needle times in hospital, from 87 minutes in GREAT (estimated mean), to 35 minutes (median) in this audit.. Call-to-opiate times give an indication of the first opportunity for thrombolysis, which may be initiated about 15 minutes after opiate is given. In both prehospital and hospital groups, median call-to-opiate times were about half an hour.. In some rural areas of Scotland, thrombolytic treatment is given by general practitioners in community ...
Purdue University, 610 Purdue Mall, West Lafayette, IN 47907, (765) 494-4600. © 2015 Purdue University , An equal access/equal opportunity university , Copyright Complaints , Maintained by Office of XYZ. Trouble with this page? Disability-related accessibility issue? Please contact Office of XYZ at [email protected] ...
Attribution: © Aberdeenshire Archaeological Service. You may: copy, display, store and make derivative works [eg documents] solely for licensed personal use at home or solely for licensed educational institution use by staff and students on a secure intranet.. Under these conditions: Display Attribution, No Commercial Use or Sale, No Public Distribution [eg by hand, email, web]. Full Terms & Conditions and Licence details. ...
All data on NatureShare is licensed under a Creative Commons Attribution 2.5 Australia License . Free: NatureShare is, and will always be, a free and open service. Warranty: NatureShare services and all software are provided on an as is basis without warranties of any kind, either express or implied, including, without limitation, fitness for a particular purpose. Your use of the services is at your sole risk. We do not guarantee the accuracy or timeliness of information available from the service. Copyright: NatureShare software is copyright Reilly Beacom (2014) (Australia) ...
Common areas. As is expected of such a long-established, community based facility you will feel as though you are entering a calm and welcoming home-like environment. Residents are provided with large, open lounge areas, comfortably furnished with individual recliner chairs and couches, and large TV (LCD) screens for ease of viewing, or may escape into quieter sitting rooms. Fresh, daily-made meals are served in the large open dining areas or alternatively there is a private dining room for residents and family, designed to make you feel relaxed and at home.. Sweeping gardens with uninterrupted views to the Grampians provide space to stroll and relax within private and secure outdoor areas that incorporate courtyards, established trees, manicured gardens and raised garden beds, and peaceful retreats maintained by community volunteers. All of this and yet only a short walk into the centre of town, where an array of shops and local businesses boast services for your convenience.. In addition to ...
Following the recent success of the smoking cessation sessions at RGU, we followed up with the two advisors from NHS Grampian who ran the sessions. As a whole the sessions were a great success. Two people followed the journey through to the quitting stage, which is really exciting, well done to them! Other people managed…
This paper forms the second part of the debate on prehospital thrombolysis (PHT). It is argued that large scale studies have failed to show a benefit for PHT, even when the time saved over conventional treatment was considerably greater than would be the case in the UK urban setting. In practice, a relatively small proportion of the total population receiving thrombolysis would receive PHT. Other strategies to reduce time to thrombolysis can benefit all patients and are likely to be more cost effective and safer.. ...
Streptokinase (SK) is a bacterial protein used clinically as a thrombolytic agent in humans. Administration of SK causes a rapid increase in the frequency of anti-SK T cells and the titre of specific anti-SK antibodies that, on subsequent administration of SK, may neutralize the activity of the drug or elicit allergic-type reactions. By locating and modifying the immunogenic T-cell epitopes within the SK protein, it is possible that an agent with reduced immunogenicity but equal efficacy may be produced. We have investigated the T-cell epitopes within SK using nine non-overlapping, recombinant peptide fragments of SK. We investigated the proliferative T-cell response of peripheral blood mononuclear cells obtained from patients before and 6 days after administration of SK for myocardial infarction. We also examined the response of cultured anti-SK T-cell lines derived from patients 6 days after treatment with SK. Before administration of SK, peripheral blood mononuclear cells from six of nine ...
Lambs!. Eastertime is here and the egg rolling done happened and the shiny guy got nailed already! Me, I was up in the Grampian hills around New Pitsligo checking out those magnificent Recumbent Stone Circles. Ive now been to 87 of them and theres at least 15 more on my list I just gots to see. If the next shamanic generation is really on its way, then I reckon Grampian is gonna be the place for the main axis of the scene. Its cheap, far away and the temples are already in place. All we gotta do is crawl up there. And these places are so overlooked that I found loads of Neolithic tools still wedged between a Recumbent stone and its flanker at one temple - beautiful sparkling things that must have lain there for millennia. I gotta go back there because theres more just waiting, so dont expect me to clue you in to what circle it was. Hey, and I even took a photo of St. Kanes church in New Deer. Kane? Saint Kane? Are we talking reluctant Christianity here or what?. Lambs! Running around the ...
What number of various positions have you possessed the capacity to incorporate? Its sensors convey through Bluetooth with an application for iOS cell phones. The recorded therapeutic information that remaining parts mysterious however can be shared not exclusively to perform with companions at the same time, ideally, to impart profitable data to your specialist for instance. An extremely shrewd condom, so, for a similarly savvy utilize, we trust.. Numerous men after spinal string damage encounter changes in their sexual capacity (and enthusiastic issues can be added to them that further influence sexuality). It is critical that the man and his partner are educated about the idea of the issues and the chances to confront them. You also need to know Is urethral insertion safe?. Male sexual capacity Regularly the male presents two sorts of erection, the psychogenic and the reflex. Psychogenic erection is controlled by the mind, because of visual, sound-related or mental upgrades. The flag from the ...
DALLAS - The use of thrombolytics before angioplasty or stenting offers no benefit and appears to increase the risk of heart attacks, strokes, or death.
Now complete, Bennetts Associates Suttie Centre aims to forge links between medical teaching and clinical practice. The £21m project is a partnership between the University of Aberdeen and NHS Grampian housing state-of-the-art teaching and learning
Do you want to stop smoking but dont know where to start? Over the coming months, in conjunction with NHS Grampian, we will be offering Smoking Cessation advice, group sessions and drop in opportunities for all students and staff on campus. Promotional material will be available in the next couple of weeks, with sessions starting in…
A new study into the treatment of gallbladder stones, which lead to around 80,000 operations a year, is being directed by NHS Grampian and the University of Aberdeen.
We live on 280 acres, with 1 of 2 sons & small dog, nestled under the highest peaks of the Grampians National Park, 20 kms south of Halls Gap. We operate the Grampians Paradise Camping & Caravan Parkland, a beautiful, small camping ground with shady trees, gardens, small lake & wetlands. Native birds, animals & frogs abound. Bright starry skies. Work with us on environmental projects, fencing, gardening, maintenance, personal vegie garden and fruit orchard, firewood collection, ground works, jobs about the camping ground, occasional building projects (Aidan is very into Traditonal Timber Framing and nearly always has a project on the go). Caravan accom for 1-2 people with own cooking facilities and the use of the camp kitchen and amenities in the camping ground. Require own bedding. Campground amenities building has bathrooms and laundry. No children. Some independent cooking and possibly some shared meals with family. Prefer No Smoking, and No Smoking Indoors under any circumstance. Can pick up ...
Thrombolytic drugs or clot-busters are used to dissolve blood clots that are blocking blood flow to the heart. When given soon after a heart attack begins, these drugs can limit or prevent permanent damage to the heart. To he most effective, these drugs need to be administered within one hour from the commencement of the attack. ...
Two special forums will be held in Ararat and Horsham. Thanks to a generous contribution from RACV, and local support from Grampians Integrated Cancer Service, these forums will be free.
By ROSALIND GRIFFITHS A MAN who had a lung removed by surgeons in Aberdeen after a mistaken cancer diagnosis is claiming compensation from NHS Grampian. Former firefighter Laurie Ball, 58, from Mossbank, was told shortly after the operation that he did not have cancer, but he said that he has had neither an
Numerous randomised trials have shown that thrombolytic treatment reduces mortality from acute myocardial infarction irrespective of the patients age, sex, blood pressure, and previous history of myocardial infarction or diabetes.1 Maximum benefit, however, is seen in those patients treated within 4-6 hours of their symptoms starting. Patients do not always seek medical help soon enough, and this accounts for much of the delay in receiving thrombolytic treatment, but important delays also occur in hospital. These are not related to the route by which the patient is admitted to hospital and vary widely between hospitals.2. Although accident and emergency departments are in an important position to minimise any delay in giving thrombolytic treatment, a recent questionnaire study of junior hospital doctors in Scotland showed that thrombolysis is rarely given in accident and emergency departments there.3 We surveyed consultants in accident and emergency departments … ...
THE Geelong region has just shivered through a week of icy weather with Aireys Inlet recording its coldest first 10 days of May on record. Sheep are now shorn in autumn for greater profits, argues a reader. Snow has fallen on the Grampians range
Australias Grampians provide travel columnist Lindsay Hawdon and her family with extraordinary landscapes and adventure… but will there be roos?
Britton Streptokinase is a medicine available in a number of countries worldwide. A list of US medications equivalent to Britton Streptokinase is available on the Drugs.com website.
Objective: To examine the association between hypertensive diseases of pregnancy (gestational hypertension and pre-eclampsia) and the development of circulatory diseases in later life.. Design: Cohort study of women who had pre-eclampsia during their first singleton pregnancy. Two comparison groups were matched for age and year of delivery, one with gestational hypertension and one with no history of raised blood pressure.. Setting: Maternity services in the Grampian region of Scotland.. Participants: Women selected from the Aberdeen maternity and neonatal databank who were resident in Aberdeen and who delivered a first, live singleton from 1951 to 1970.. Main outcome measures: Current vital and cardiovascular health status ascertained through postal questionnaire survey, clinical examination, linkage to hospital discharge, and mortality data.. Results: There were significant positive associations between pre-eclampsia/eclampsia or gestational hypertension and later hypertension in all measures. ...
Acute stroke is the third leading cause of mortality in developed countries and the major medical cause of disability in adults. The outcome can be improved by early treatment with thrombolysis. Alteplase (r-tPA) is the only approved thrombolytic drug in the indication of acute ischemic stroke. However, the use of alteplase is currently restricted by the need to administer it within 3 hours of symptom onset. As the risk of transforming a cerebral infarct into haemorrhage probably rises as the time elapsed increases, a thrombolytic drug that carries a lower risk of haemorrhage than alteplase may offer a wider time-to-treatment window and improve the safety profile ...
I first published this story back in April 2015. Recently, I spoke about this weevil on ABC Radio Ballarat and also at a talk I gave to Friends of the Grampians Gariwerd (FOGG) so I thought now is a good time to republish.. I found this fellow trundling along the road when I went for my morning walk the other day. This insect is commonly known as a Botany Bay weevil (Chrysolopus spectabilis) or by its other common name "diamond weevil". This is the male of the species. Females are larger insects, making males the lesser of two weevils (sorry, I couldnt resist!).. ...
Balmoral castle, Scottish castle, accommodation & cottage holidays in Scotland. Fly fishing, home of the Queen, holiday cottages, days out in Grampian, great castle estate and holidays in Scotland.
A mother who was told she had terminal cancer arranged her funeral and wrote farewell letters to her young sons - only to be told the diagnosis was a mistake.. Denise Clark, 34, said her life was made "absolute hell" for two years after she was given the wrong prognosis at Aberdeen Royal Infirmary.. She spent £10,000 on treatment at an alternative therapy clinic in Spain in the hope of prolonging her life and went on what she thought was a last summer holiday with her family.. But after growing suspicious about how well she was feeling, Ms Clark demanded another scan - which revealed the growth in her pelvis was not malignant after all.. Now the mum of two has settled a claim for a high five-figure sum after she raised proceedings against NHS Grampian following the errors in her care.. Ms Clark, mother to Harvey, 10, and Luca, four, said she hoped no one else would suffer the heartache she had gone through.. "Hearing them say it was a mistake was amazing and there is a future now, but it ...
Appeals were made in local newspapers about three vehicles - a silver saloon, a red VW Golf and a blue Rover - sighted at different times in the layby near Donovans car.. Police were also puzzled by the dead mans last movements. At the time police said he had been reported missing from his home the weekend before his body was found, and they were baffled by the remote location more than 40 miles north of Aberdeen.. Detectives from Grampian CID also travelled to London, where they found Donovans widow to be "upset but quite pleasant".. They went to a gym connected to the crime gang and spoke to management, and also interviewed the underworld enforcer who had been linked to Donovan.. The Operation Tiberius report stated Scottish liaison was handled by a detective constable at the Met and Grampian officers "remain unaware of SIS interest in these matters".. It went on: "It is understood that Grampian CID eventually wrote off the incident as a suicide.". There is little further mention of Donovan ...
The APSACs recommendations focus on the diagnosis and assessment of attachment problems in children, along with treatments and interventions as well as recommendations for child welfare agencies. Regarding diagnosis and assessment, the APSAC advises that attachment problems, including but extending beyond RAD, are an appropriate concern for professionals who work with maltreated children and should be carefully considered when these children are assessed. The term "attachment disorder" is not part of any accepted system for classifying behavioral or mental disorders; however, there is a narrower and better accepted condition called "reactive attachment disorder" (RAD), which is described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). The core feature of RAD is severely inappropriate social relating that begins before age 5 years. RAD symptoms typically involve one of two extreme behaviors: indiscriminate and excessive attempts to receive comfort and affection from any ...
The early determination of whether a patient presenting with chest pain is truly having an MI has 2 important ramifications, only 1 of which is addressed by Puleo and colleagues. The authors rightly point out that resources are wasted when patients without MIs are placed in units designed to care for patients with MIs. Another important aspect of an early and accurate diagnosis of infarction is to allow for early treatment with thrombolytic drugs. This study clearly shows that CK-MB subforms detect MI within 6 hours after the onset of symptoms. It is clear that patients presenting with "big-bang" infarctions (i.e., significant ST-segment elevation) will need to receive thrombolytic drugs as early as possible and that in this group of patients an elevation of CK-MB subform would be of little value. The management of patients with a good history and equivocal electrocardiographic changes can be more difficult. Thus, although providing valuable information on the sensitivity and specificity of ...
In a nutshell:​ If you take more than an idle interest in our feathered friends, privately owned Faccenda Group is your employer of choice. The second largest chicken processor in the UK after Grampian Country Food Group, Faccenda is a fully integrated agriculture and chicken processing business handling more than 2m birds a week from facilities across the UK. History:​ Established over 40 years ago by Sunday Times rich list regular Robin Faccenda and family, Faccenda has grown through a series of acquisitions including Hinton Poultry, Perry Poultry and Webbs Country Foods, and now turns over a cool £300m.. Operating from six sites in the UK, Faccenda supplies large supermarket chains and restaurants with whole chickens, breasts, chicken portions and value added products. Brands youd recognise:​ You wont. Faccenda supplies own-label products.. The strategy:​ Sticking to its knitting and keeping customers happy with high quality whole chickens and chicken portions, plus more value ...
Intravenous Thrombolytic Therapy clinics in France at the best price. Find doctors, specialized in Vascular Medicine and compare prices, costs and reviews.
Eminase (anistreplase). *Engerix-B (hepatitis B vaccine). *Floxapen (flucloxacillin). *granisetron. *Havrix (hepatitis A ...
B01AD03 Anistreplase. B01AD04 Urokinase. B01AD05 Fibrinolysin. B01AD06 Brinase. B01AD07 Reteplase. B01AD08 Saruplase. B01AD09 ...
... anistreplase). ...
... anistreplase MeSH D12.776.124.125.662.537.900 -- streptodornase and streptokinase MeSH D12.776.124.125.662.768 -- tissue ...
... anistreplase (INN) anitrazafen (INN) anivamersen (USAN, INN) Anodynos-DHC Anolor 300 Anoquan anpirtoline (INN) anrukinzumab ( ...
... anistreplase MeSH D08.811.277.656.300.760.640 --- proprotein convertase 1 MeSH D08.811.277.656.300.760.646 --- proprotein ... anistreplase MeSH D08.811.277.656.300.775.900 --- streptodornase and streptokinase MeSH D08.811.277.656.350 --- exopeptidases ...
Some fibrinolytics are: Streptokinase (Kabikinase) Urokinase Anistreplase (Eminase) Recombinant tissue plasminogen activators ( ...
... and anistreplase to each other, and also compared the anticoagulant heparin to no heparin. All patients were also given aspirin ... a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin ...
... is a thrombolytic drug. Anistreplase has been developed by Beecham as Eminase. It is also known as anisoylated ... Grampion Region Early Anistreplase Trial (GREAT)". J Epidemiol Community Health. 47 (5): 377-381. doi:10.1136/jech.47.5.377. ... "Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners". Br J Gen Pract. 45 ... new evidence from Grampian region early anistreplase trial (GREAT)". BMJ. 312 (7025): 212-5. doi:10.1136/bmj.312.7025.212. PMC ...
When plasmin breaks down fibrin, a number of soluble parts are produced. These are called fibrin degradation products (FDPs). FDPs compete with thrombin, and thus slow down clot formation by preventing the conversion of fibrinogen to fibrin. This effect can be seen in the thrombin clotting time (TCT) test, which is prolonged in a person that has active fibrinolysis.. FDPs, and a specific FDP, the D-dimer, can be measured using antibody-antigen technology. This is more specific than the TCT, and confirms that fibrinolysis has occurred. It is therefore used to indicate deep-vein thrombosis, pulmonary embolism, DIC and efficacy of treatment in acute myocardial infarction. Alternatively, a more rapid detection of fibrinolytic activity, especially hyperfibrinolysis, is possible with thromboelastometry (TEM) in whole blood, even in patients on heparin. In this assay, increased fibrinolysis is assessed by comparing the TEM profile in the absence or presence of the fibrinolysis inhibitor aprotinin. ...
In 2001, Eli Lilly's chairman, president and CEO, Sidney Taurel, told shareholders: "No medicine better symbolizes our mission than Xigris," calling it "one of our industry's genuine breakthroughs."[5]. Xigris was designed to fight sepsis, a condition that kills more than 200,000 Americans annually. It was the only approved drug for sepsis, and it costs $8,000 to treat a single patient. Lilly hoped it would be a blockbuster, with sales of at least a billion dollars a year. But after five years on the market, sales were only $200 million.. Eli Lilly used the Belsito & Company PR firm in a marketing campaign to promote Xigris, its drug for treatment of sepsis. A report in the New England Journal of Medicine (NEJM) accused the company of initiating false reports of a shortage of the drug to boost sales.[6] Belsito and Company spread the word that the drug was being "rationed" and physicians were being 'systematically forced' to decide who would live and who would die. As part of this effort, Lilly ...
Acetylsalicylic acid is a weak acid, and very little of it is ionized in the stomach after oral administration. Acetylsalicylic acid is quickly absorbed through the cell membrane in the acidic conditions of the stomach. The increased pH and larger surface area of the small intestine causes aspirin to be absorbed more slowly there, as more of it is ionised. Owing to the formation of concretions, aspirin is absorbed much more slowly during overdose, and plasma concentrations can continue to rise for up to 24 hours after ingestion.[152][153][154] About 50-80% of salicylate in the blood is bound to albumin protein, while the rest remains in the active, ionized state; protein binding is concentration-dependent. Saturation of binding sites leads to more free salicylate and increased toxicity. The volume of distribution is 0.1-0.2 L/kg. Acidosis increases the volume of distribution because of enhancement of tissue penetration of salicylates.[154] As much as 80% of therapeutic doses of salicylic acid is ...
The drug is clear with a pH of 10.[7] Its production is inhibited indirectly by NSAIDs, which inhibit the cyclooxygenase enzymes COX1 and COX2. These convert arachidonic acid to prostaglandin H2 (PGH2), the immediate precursor of prostacyclin. Since thromboxane (an eicosanoid stimulator of platelet aggregation) is also downstream of COX enzymes, one might think that the effect of NSAIDs would act to balance. However, prostacyclin concentrations recover much faster than thromboxane levels, so aspirin administration initially has little to no effect but eventually prevents platelet aggregation (the effect of prostaglandins predominates as they are regenerated). This is explained by understanding the cells that produce each molecule, TXA2 and PGI2. Since PGI2 is primarily produced in a nucleated endothelial cell, the COX inhibition by NSAID can be overcome with time by increased COX gene activation and subsequent production of more COX enzymes to catalyze the formation of PGI2. In contrast, TXA2 is ...
... (Ro 48-3657, proposed brand name Xubix) is the double prodrug of Ro-44-3888, which is a platelet aggregation inhibitor. It was being developed for secondary prevention of arterial thrombosis following unstable angina pectoris and acute myocardial infarction (MI). On August 6, 1999, Hoffmann-La Roche announced that the preliminary results from Phase III clinical trials had not shown that sibrafiban was better than aspirin in preventing recurrent ischemic events in patients suffering from acute coronary syndrome. The development of sibrafiban was terminated. ...
In industry, EDTA is mainly used to sequester metal ions in aqueous solution. In the textile industry, it prevents metal ion impurities from modifying colors of dyed products. In the pulp and paper industry, EDTA inhibits the ability of metal ions, especially Mn2+, from catalyzing the disproportionation of hydrogen peroxide, which is used in chlorine-free bleaching. In a similar manner, EDTA is added to some food as a preservative or stabilizer to prevent catalytic oxidative decoloration, which is catalyzed by metal ions.[4] In soft drinks containing ascorbic acid and sodium benzoate, EDTA mitigates formation of benzene (a carcinogen).[5] The reduction of water hardness in laundry applications and the dissolution of scale in boilers both rely on EDTA and related complexants to bind Ca2+, Mg2+, as well as other metal ions. Once bound to EDTA, these metal centers tend not to form precipitates or to interfere with the action of the soaps and detergents. For similar reasons, cleaning solutions often ...
As of March 2017, brands included Aclop, Actaclo, Agregex, Agrelan, Agrelax, Agreless, Agrelex, Agreplat, Anclog, Angiclod, Anplat, Antiagrex, Antiban, Antigrel, Antiplaq, Antiplar, Aplate, Apolets, Areplex, Artepid, Asogrel, Atelit, Atelit, Ateplax, Atervix, Atheros, Athorel, Atrombin, Attera, Bidogrel, Bigrel, Borgavix, Carder, Cardogrel, Carpigrel, Ceraenade, Ceruvin, Cidorix, Clatex, Clavix, Clentel, Clentel, Clidorel, Clodel, Clodelib, Clodian, Clodil, Cloflow, Clofre, Clogan, Clogin, Clognil, Clogrel, Clogrelhexal, Clolyse, Clont, Clood, Clopacin, Clopcare, Clopeno, Clopex Agrel, Clopez, Clopi, Clopid, Clopida, Clopidep, Clopidexcel, Clopidix, Clopidogrel, Clopidogrelum, Clopidomed, Clopidorex, Clopidosyn, Clopidoteg, Clopidowel, Clopidra, Clopidrax, Clopidrol, Clopigal, Clopigamma, Clopigrel, Clopilet, Clopimed, Clopimef, Clopimet, Clopinovo, Clopione, Clopiright, Clopirite, Clopirod, Clopisan, Clopistad, Clopistad, Clopitab, Clopithan, Clopitro, ClopiVale, Clopivas, Clopivaz, Clopivid, ...
Anistreplase) · 孟替普酶(英語:Monteplase) 其他絲氨酸內肽酶: 安克洛酶(英語:Ancrod) · 纖維蛋白酶(英語:Brinase
Anistreplase) · 孟替普酶(英语:Monteplase) 其他丝氨酸内肽酶: 安克洛酶(英语:Ancrod) · 纤维蛋白酶(英语:Brinase
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.. ...
Anistreplase is a thrombolytic drug. Anistreplase has been developed by Beecham as Eminase. It is also known as anisoylated ... Grampion Region Early Anistreplase Trial (GREAT)". J Epidemiol Community Health. 47 (5): 377-381. doi:10.1136/jech.47.5.377. ... "Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners". Br J Gen Pract. 45 ... new evidence from Grampian region early anistreplase trial (GREAT)". BMJ. 312 (7025): 212-5. doi:10.1136/bmj.312.7025.212. PMC ...
Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen- ... Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots. ... Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the ... Anistreplase. Accession Number. DB00029 (BTD00102, BIOD00102) Type. Biotech. Groups. Approved. Biologic Classification. Protein ...
Find information on Anistreplase (anisoylated plasminogen-streptokinase activator complex, APSAC) in Daviss Drug Guide ... anistreplase is a topic covered in the Daviss Drug Guide. To view the entire topic, please sign in or purchase a subscription. ... "Anistreplase." Daviss Drug Guide, 16th ed., F.A. Davis Company, 2020. Nursing Central, nursing.unboundmedicine.com/ ... nursingcentral/view/Davis-Drug-Guide/109358/all/anistreplase. Quiring C, Sanoski CA, Vallerand AH. Anistreplase. Daviss Drug ...
anistreplase. (redirected from anisoylated plasminogen streptokinase activator complex). Also found in: Acronyms. anistreplase ... anistreplase. See APSAC. anistreplase. A clot-dissolving drug used to try to re-establish blood flow in the heart muscle in the ... anistreplase. /an·is·trep·lase/ (an″is-trep´lās) a thrombolytic agent used to clear coronary vessel occlusions associated with ... anistreplase. a plasminogen activator. indication This drug is used in acute MI for lysis of coronary artery thrombi. ...
Eminase (anistreplase). *Engerix-B (hepatitis B vaccine). *Floxapen (flucloxacillin). *granisetron. *Havrix (hepatitis A ...
B01AD03 Anistreplase. B01AD04 Urokinase. B01AD05 Fibrinolysin. B01AD06 Brinase. B01AD07 Reteplase. B01AD08 Saruplase. B01AD09 ...
Cardioprotection and Thrombolysis by Anistreplase in Anesthetized Dogs. Feuerstein, Giora Z.; Nichols, Andrew J.; Valocik, ...
Eminase (Anistreplase). EMINASE® Roberts Anistreplase Fibrinolytic Agent Action And Clinical Pharmacology: Anistreplase is an ...
Detailed drug Information for dabigatran. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
This medicine may increase your chance of bleeding or bruising. This risk is higher if you have poorly controlled high blood pressure, a heart infection, ulcers of the stomach, or other bleeding problems. Check with your doctor right away if you notice any unusual bleeding or bruising, black, tarry stools, blood. in the urine or stools, or pinpoint red spots on your skin. Avoid picking your nose. If you need to blow your nose, blow it gently. This medicine may increase your chance of serious bleeding or nerve problems in your spine. This risk is higher if you have a catheter in your back for pain medicine or anesthetics, or have an injection into your spine (sometimes called an "epidural" or "spinal"). Other things that increase this risk are traumatic or repeated epidural or spinal punctures in the past, spinal deformity, previous spinal surgery, or use of other medications that increase the risk of bleeding. Check with your doctor right away if you develop weakness or numbness in your legs or ...
Detailed drug Information for protein c, human Intravenous. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
... followed by anistreplase in the hospital (hospital group). Prehospital therapy was administered by emergency medical personnel ... of the onset of symptoms who had a qualifying 12-lead electrocardiogram were randomly assigned to receive either anistreplase ...
Anistreplase (major, theoretical). *Argatroban (major, theoretical). *Aspirin (major, theoretical). *. B*Bivalirudin (major, ...
ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs ...
A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator ... OBJECTIVES: We designed a randomized trial to evaluate the effects of heparin administration in conjunction with anistreplase ( ... A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator ...
... anistreplase and/or derivatives thereof; antagonists of vascular epithelial growth factor and/or derivatives thereof; anti- ...
Anistreplase. An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is ...
Anistreplase. An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is ...
Anistreplase. Plasminogen activator inhibitor 1. target. DB00031. Tenecteplase. Urokinase plasminogen activator surface ... Anistreplase. For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction. ...
Anistreplase is not being used for peripheral vascular work. Several other new thrombolytic agents are under review, but only ... Anistreplase is an equimolar complex of streptokinase and para -anisoylated human Lys-plasminogen, or anisoylated plasminogen- ...
... anistreplase, streptokinase and urokinase; hormones and hormone modifiers, such as bromocriptine; abortifacients, such as ... anistreplase, streptokinase, and urokinase; dermatological agents, such as colchicine, isotretinoin, methotrexate, minoxidil, ... anistreplase, brinase, drotrecogin alfa, fibrinolysin, procein C, reteplase, saruplase, streptokinase, tenecteplase, and ... anistreplase, streptokinase and urokinase; antiemetics, such as prochlorperazine; salicylate gastrointestinal anti-inflammatory ...
Study Similar Drugs flashcards from Suzie Ilagan
Anistreplase (Apsac). 12. Aspirin (Acetylsalicylic Acid). 13. Atenolol. 14. Atracurium. 15. Atropine. 16. Bretylium. 17. ...
Anistreplase, the thrombolytic agent used in GREAT, could be given as a single injection, which enabled domiciliary use. ... Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region early anistreplase trial (GREAT). J Am Coll ... who were seen by their general practitioner within four hours of symptom onset and were given intravenous anistreplase either ...
  • Bar and colleagues expressed about the matter: "Angiographic but no clinical improvement after thrombolytic treatment with anistreplase was found in patients with unstable angina with an excess of bleeding complications. (positivehealth.com)
  • The therapeutic efficacy of Anistreplase can be increased when used in combination with (1,2,6,7-3H)Testosterone. (drugbank.ca)
  • The therapeutic efficacy of Anistreplase can be increased when used in combination with 18-methyl-19-nortestosterone. (drugbank.ca)
  • In a multicenter, double-blind study, patients seen within six hours of the onset of symptoms who had a qualifying 12-lead electrocardiogram were randomly assigned to receive either anistreplase before admission, followed by placebo in the hospital (prehospital group), or placebo before admission, followed by anistreplase in the hospital (hospital group). (nih.gov)
  • The study enrolled patients who were treated with anistreplase. (ebscohost.com)
  • actavis seeks fda approval for generic Anistreplase to treat pah patients. (sovawinetrail.com)